Newsletter | August 26, 2026

08.26.26 -- The 3 Pillars Of Next-Gen mRNA Expansion

SPONSOR

This Advancing RNA discussion will be a deep dive into the world of plasmid sourcing and quality considerations. What quality attributes matter the most for producing the desired quality of mRNA? What are the current gaps in our knowledge of plasmid quality, and how are we as an industry striving to close these gaps? Register today and find out.

FEATURED EDITORIAL

From Baby KJ To Global Access: The 3 Pillars Of Next-Gen mRNA Expansion

The transition from RNA vaccines to therapeutics is an “expansion” all on its own; but to do this successfully, we need to expand our science, our products’ deliverability, and our patient access. In the following article, I highlight a few of the best practices and/or innovations that came up in conversation during this event that will play a significant role in helping us expand mRNA’s reach, both scientifically and therapeutically.

Harnessing Regulatory RNAs To Increase Haploinsufficient Gene Expression

Can RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.

How Non-Canonical RNA Capping Could Expand RNA Therapeutics

Newly discovered non-canonical RNA caps are reshaping RNA biology and could inspire the next generation of more precise, programmable RNA therapeutics.

Decoding How HNRNPD Shapes circRNA Biogenesis And RNA Fate

How do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.

INDUSTRY INSIGHTS

Twist Of Two: Characterizing Oligonucleotides Using Orthogonal 2D-LC

Discover how coupling orthogonal mechanisms reveals hidden impurities and creates a more robust strategy for characterizing complex oligonucleotide samples.

Resilience By Design: Lessons From Real-World Disruption

Resilience is the bridge to patient access. Learn how to design your logistics with intentional flexibility to withstand real-world disruptions and protect product integrity under pressure.

The Evolving Regulatory Landscape For Plasmid DNA In Gene Therapy

Explore how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.

Safeguarding Product Integrity Throughout The Cold Chain

Temperature-controlled storage, continuous monitoring, and strict safeguards keep biologic materials stable, preventing degradation from initial fill to final patient.

Usable RNA Output: A More Complete Way To Evaluate IVT Performance

Total RNA yield alone doesn't tell the full story of IVT performance. Learn why usable target RNA output is the metric that matters most as programs advance toward manufacturing.

Defining Analytical Frameworks For Next-Generation mRNA Therapies

Identify and understand the use of cutting-edge technologies to assess the critical quality attributes of both mRNA drug substances and drug products.

Optimizing Large-Scale mRNA Processes In A cGMP Environment

Commercial production requires validated, highly reproducible workflows. Examine emerging technologies designed to streamline process development in regulated environments.

Nucleic Acid-LNP Ultrafiltration And Diafiltration

Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

SPONSOR

Webinar: Autonomous Impinging Jet Mixing for LNP Process Development

Lipid nanoparticle (LNP) development can be slow and resource-intensive. Discover how impinging jet mixing, automation, inline analytics, and data-driven optimization can accelerate process development and enable more predictive manufacturing. This Knauer webinar will explore closed-loop experimentation, automated design of experiments, self-optimization, and modeling approaches that can help identify robust conditions faster and support scalable, reproducible LNP production. Click here to learn more.

SOLUTIONS

Advance Your Lead Oligonucleotide Candidates From Discovery To Market

End-To-End mRNA Vaccines And Therapeutics Services

In Vitro Transcription For mRNA Production

Speed, Precision, Impact: The CRO Revolutionizing Bioanalysis